Forecasted · Cooperative Agreement
Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
National Institutes of Health, Department of Health and Human Services
Key facts
Copied from the official Grants.gov record. Last verified October 29, 2026.
- Program name
- Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
- Issuing agency
- National Institutes of Health (Department of Health and Human Services)
- Opportunity number
- PAR-27-125
- Funding type
- Cooperative Agreement
- Funding purpose
- Health
- Status
- Forecasted
- Application deadline
- Forecasted · estimated close February 16, 2027 (agency estimate)
- Agency estimates
- Estimated posting: November 16, 2026. Estimated award date: October 1, 2027. Estimates can change.
- Published award range
- Not published by the agency
- Cost sharing or match required
- No
- Eligible applicants (official categories)
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see Additional Information on Eligibility)
- Relevant to
- Businesses and NonprofitsHow we determined this: Grants.gov eligibility includes small businesses or for-profit organizations. Grants.gov eligibility includes nonprofit organizations.
- Geographic restrictions
- None stated in structured data (federal opportunities are often nationwide). Check the eligibility details and full announcement for any limits.
- Assistance Listing (CFDA)
- 93.233, 93.837, 93.838, 93.839, 93.840
- Official source
- View on Grants.gov ↗
- Application URL
- www.grants.gov/search-results-detail/363025 ↗Apply through Grants.gov (Workspace) using the application package on the official listing, unless the full announcement names a different submission system.
- Source identifier
- Grants.gov opportunity ID 363025 · Funding opportunity number PAR-27-125
- Posted
- July 1, 2026 · Source last updated July 1, 2026
- Last verified
- October 29, 2026 (against Grants.gov)
- Data completeness
- 92% of key fields published by the sourceNot published: published funding range.
- Record confidence
- mediumforecast — dates and amounts are agency estimates.
Eligibility details (from the agency)
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Description (from the official listing)
The NIH intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications to develop and implement investigator-initiated multi-site clinical trials, including efficacy, effectiveness, pragmatic, and/or implementation research clinical trials. Applications that propose a large and/or complex clinical trial conducted at either a single site or at multiple locations but without physical clinical sites (e.g., decentralized or virtual trials) may also be eligible. Proposed trials must be relevant to the research mission of the participating ICs and meet the NIH definition of a clinical trial (see NOT-OD-15-015 and NOT-OD-26-032). The objective of the application is to present 1) the scientific rationale as well as a comprehensive scientific and operational plan for the trial, and 2) a comprehensive plan to provide overall project coordination, administration, data management, and biostatistical support for the clinical trial. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO will utilize a bi-phasic (UG3/UH3), milestone-driven mechanism consisting of a start-up phase up to 2 years (UG3) and a full enrollment and clinical trial implementation phase up to 5 years (UH3), for a total award duration of up to 7 years. A UG3 project that meets its milestones will be administratively considered for transition to the UH3 award. Investigators with expertise and insights into this area are encouraged to begin to consider applying…
Read the full description
The NIH intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications to develop and implement investigator-initiated multi-site clinical trials, including efficacy, effectiveness, pragmatic, and/or implementation research clinical trials. Applications that propose a large and/or complex clinical trial conducted at either a single site or at multiple locations but without physical clinical sites (e.g., decentralized or virtual trials) may also be eligible. Proposed trials must be relevant to the research mission of the participating ICs and meet the NIH definition of a clinical trial (see NOT-OD-15-015 and NOT-OD-26-032). The objective of the application is to present 1) the scientific rationale as well as a comprehensive scientific and operational plan for the trial, and 2) a comprehensive plan to provide overall project coordination, administration, data management, and biostatistical support for the clinical trial. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO will utilize a bi-phasic (UG3/UH3), milestone-driven mechanism consisting of a start-up phase up to 2 years (UG3) and a full enrollment and clinical trial implementation phase up to 5 years (UH3), for a total award duration of up to 7 years. A UG3 project that meets its milestones will be administratively considered for transition to the UH3 award. Investigators with expertise and insights into this area are encouraged to begin to consider applying for this NOFO.
Agency contact
National Heart, Lung, and Blood Institute (NHLBI)
NHLBIDCVSClinical@mail.nih.gov